27 Apr 2020
AACR2020: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States
Upcoming Investor Events
Learn More
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
European Lung Cancer Congress 2022
Final OS results and subgroup analysis of savolitinib Phase II study in METex14+ NSCLC
Learn More
Latest News
4 Feb 2022HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in ChinaRead more 20 Jan 2022HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in ChinaRead more 19 Jan 2022HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers SymposiumRead more
12 Jan 2022HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune ThrombocytopeniaRead more 10 Jan 2022HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in ChinaRead more 20 Dec 2021HUTCHMED Included in FTSE Russell IndexesRead more 14 Dec 2021HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual MeetingRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP
THE GROUP
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
